|
|
|
|
|
1
|
Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth |
Aug 2010 |
$7,600.00 |
|
Introduction Brazil’s retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 and 2009. Key growth drivers include the expanding population, improved access to healthcare, and the burgeoning middle class
more...
Published by: Datamonitor
|
|
|
2
|
Jazz Pharmaceuticals, Inc. (JAZZ) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Jazz Pharmaceuticals, Inc. (Jazz) is a pharmaceutical company engaged in the identification, development and commercialization of products for neurology and psychiatry. The company’s products list include Xyrem, for the treatment of cataplexy and excessive daytime
more...
Published by: GlobalData
|
|
|
3
|
West Pharmaceutical Services, Inc. (WST) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
West Pharmaceutical Services, Inc. (West Pharmaceutical) is engaged in the manufacturing of components and systems for injectable drug delivery, plastic packaging, as well as delivery system components for the healthcare, pharmaceutical and consumer products markets.
more...
Published by: GlobalData
|
|
|
4
|
Anadys Pharmaceuticals, Inc (ANDS) - Financial and Strategic Analysis Review |
Sep 2010 |
$125.00 |
|
Anadys Pharmaceuticals, Inc. (Anadys) is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections and cancer. The company is in development stage without any commercialized products. It generates
more...
Published by: GlobalData
|
|
|
5
|
Australian Pharmaceutical Industries Limited (API) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Australian Pharmaceutical Industries Limited (API) is an in-store retailer. The company is engaged in the retailing, distribution and wholesaling of beauty and health products. In addition, it also undertakes manufacturing activities through its tow plants
more...
Published by: GlobalData
|
|
|
6
|
Clinuvel Pharmaceuticals Limited (CUV) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Clinuvel Pharmaceuticals Limited (Clinuvel Pharmaceuticals) is a biopharmaceutical company engaged in the development of photoprotective drug called afamelanotide (formerly CUV1647) as a preventative treatment for a range of ultra violet (UV)-related skin disorders and also
more...
Published by: GlobalData
|
|
|
7
|
Alliance Pharmaceutical Corp. (ALLP) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Alliance Pharmaceutical Corp. (Alliance) is a pharmaceutical research and development company. The company focuses on transforming innovative scientific discoveries into novel therapeutic and diagnostic agents. The Research and Development activity of the company is principally
more...
Published by: GlobalData
|
|
|
8
|
Cortex Pharmaceuticals, Inc. (CORX) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Cortex Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurodegenerative, and neurological and psychiatric disorders. The company principally focuses on AMPAKINE molecules, targeted towards
more...
Published by: GlobalData
|
|
|
9
|
Vertex Pharmaceuticals Incorporated (VRTX) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company. It is principally engaged in the discovery, development and commercialization of small molecule drugs. The company develops products that are used in the treatment of major diseases,
more...
Published by: GlobalData
|
|
|
10
|
MiddleBrook Pharmaceuticals, Inc. (MBRK) - Financial and Strategic Analysis Review |
Sep 2010 |
$125.00 |
|
MiddleBrook Pharmaceuticals, Inc. (MiddleBrook) is a pharmaceutical company which is focused on developing and commercializing of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The company developed a
more...
Published by: GlobalData
|
|
|
11
|
ACADIA Pharmaceuticals Inc. (ACAD) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Acadia Pharmaceuticals Inc. (Acadia) is a biopharmaceutical company, engaged in discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company focuses on developing a portfolio of four
more...
Published by: GlobalData
|
|
|
12
|
NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on the development of specialty therapeutics for the treatment of gastrointestinal and endocrine disorders. The company is in the process of developing two late-stage programs namely,
more...
Published by: GlobalData
|
|
|
13
|
Oramed Pharmaceuticals, Inc. (ORMP) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Oramed Pharmaceuticals, Inc. (Oramed) is a biopharmaceutical company. It is principally engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin pill which is to be used for the treatment of
more...
Published by: GlobalData
|
|
|
14
|
Urigen Pharmaceuticals, Inc. (URGP) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Urigen Pharmaceuticals, Inc. (Urigen Pharmaceuticals) is a specialty pharmaceutical company engaged into development and commercialization of therapeutic products for urological disorders. The company's research activities are aimed at development of treatments for painful bladder syndrome,
more...
Published by: GlobalData
|
|
|
15
|
Alnylam Pharmaceuticals, Inc (ALNY) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Alnylam Pharmaceuticals, Inc., (Alnylam Pharmaceuticals) is a biopharmaceutical company engaged in the development of therapeutics based on ribonucleic acid interference (RNAi). The company's lead RNAi therapeutic program, ALN-RSV01, for the treatment of human respiratory syncytial
more...
Published by: GlobalData
|
|
|
16
|
DUSA Pharmaceuticals, Inc (DUSA) - Financial and Strategic Analysis Review |
Sep 2010 |
$125.00 |
|
DUSA Pharmaceuticals, Inc. ( DUSA) is a pharmaceutical company, engaged in the development and marketing of its Levulan Photodynamic Therapy (PDT) technology platform, for the treatment of pre-cancerous skin lesions known as Actinic Keratoses (AK).
more...
Published by: GlobalData
|
|
|
17
|
La Jolla Pharmaceutical Company (LJPC) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical Company primarily involved in developing pharmaceutical products to treat patients with lupus. The Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies
more...
Published by: GlobalData
|
|
|
18
|
Lexicon Pharmaceuticals, Inc. (LXRX) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company engaged in the discovery and development of breakthrough treatments for human diseases including immunology, metabolism, cardiology, and ophthalmology. The company is dependent on its proprietary gene knockout
more...
Published by: GlobalData
|
|
|
19
|
Lotus Pharmaceuticals, Inc. (LTUS) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Lotus Pharmaceuticals, Inc. (Lotus) is engaged in the development, manufacture and distribution of prescription drugs and pharmaceutical products. It operates and has ownership interests in Liang Fang Pharmaceutical, Ltd. (Liang) and En Zhe Jia Shi
more...
Published by: GlobalData
|
|
|
20
|
Arena Pharmaceuticals, Inc. (ARNA) - Financial and Strategic Analysis Review |
Sep 2010 |
$125.00 |
|
Arena Pharmaceuticals, Inc., (Arena) is engaged in the research and development of innovative therapies for the treatment of various diseases including obesity, diabetes, insomnia, thrombosis. It is a biopharmaceutical company conducting research programs in major
more...
Published by: GlobalData
|
|
|
21
|
Minster Pharmaceuticals plc (MPM) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Minster Pharmaceuticals plc (Minster Pharmaceuticals) is engaged in the development of compounds for the treatment of neurological and psychiatric conditions. Its pipeline products are tonabersat and sabcomeline. Tonabersat is the leading compound in an exciting
more...
Published by: GlobalData
|
|
|
22
|
Penwest Pharmaceuticals Co. (PPCO) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Penwest Pharmaceutical Co. (Penwest) is a pharmaceutical company, which is principally engaged in the development of pharmaceutical products based on proprietary drug delivery technologies and focus on disorders of the nervous system. The drug delivery
more...
Published by: GlobalData
|
|
|
23
|
Regeneron Pharmaceuticals, Inc. (REGN) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The company's product portfolio focuses on serious debilitating medical conditions
more...
Published by: GlobalData
|
|
|
24
|
Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic Analysis Review |
Sep 2010 |
$125.00 |
|
Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals) is a specialty pharmaceutical company engaged in the discovery, development and marketing of small molecule pharmaceutical products for the treatment of orphan neuromuscular diseases. Santhera currently has three different
more...
Published by: GlobalData
|
|
|
25
|
SciClone Pharmaceuticals, Inc. (SCLN) - Financial and Strategic Analysis Review |
Aug 2010 |
$125.00 |
|
SciClone Pharmaceuticals, Inc. (SciClone) is engaged in the development of novel therapies for cancer and infectious diseases. The company's primary product, ZADAXIN, is marketed in over 30 countries for the treatment hepatitis B virus (HBV)
more...
Published by: GlobalData
|
|
|
|
|
|
0 items
